Login / Signup

Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria.

Amol T KothekarJigeeshu Vasishtha DivatiaSheila Nainan MyatraAnand PatilManjunath Nookala KrishnamurthyHarish Mallapura MaheshwarappaSuhail Sarwar SiddiquiMurari GurjarSanjay BiswasVikram Gota
Published in: Annals of intensive care (2020)
In patients with severe sepsis or septic shock, EI of 1000 mg of meropenem over 3 h administered Q8H is inadequate to provide activity (fT > 4 µg/mL > 40) against strains susceptible to increased exposure, which requires a bolus of 500 mg followed by EI of 1500 mg Q8H. While fT > 8 µg/mL > 40 require escalation of EI dose, fT > 4 µg/mL = 100 and fT > 8 µg/mL = 100 require escalation of both EI dose and frequency.
Keyphrases
  • septic shock
  • early onset
  • open label
  • escherichia coli
  • low dose
  • gram negative
  • randomized controlled trial
  • intensive care unit
  • stem cells
  • clinical trial
  • multidrug resistant
  • acute kidney injury
  • bone marrow